Sign in or Register   Sign in or Register
  |  

Mouse Anti-MSLN Recombinant Antibody (CBFYM-2650) (CBMAB-M2839-FY)

This product is mouse antibody that recognizes MSLN. The antibody CBFYM-2650 can be used for immunoassay techniques such as: ELISA, IHC, WB.
See all MSLN antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBFYM-2650
Antibody Isotype
IgG2a
Application
ELISA, IHC, WB

Basic Information

Immunogen
Recombinant protein corresponding to the extracellular domain of human mesothelin
Specificity
Human
Antibody Isotype
IgG2a
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
0.02 M Potassium phosphate, 0.15 M NaCl, pH 7.2
Preservative
0.01% Sodium azide
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Mesothelin
Introduction
This gene encodes a preproprotein that is proteolytically processed to generate two protein products, megakaryocyte potentiating factor and mesothelin. Megakaryocyte potentiating factor functions as a cytokine that can stimulate colony formation of bone marrow megakaryocytes. Mesothelin is a glycosylphosphatidylinositol-anchored cell-surface protein that may function as a cell adhesion protein. This protein is overexpressed in epithelial mesotheliomas, ovarian cancers and in specific squamous cell carcinomas. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed.
Entrez Gene ID
10232
UniProt ID
Q13421
Alternative Names
Mesothelin; Pre-Pro-Megakaryocyte-Potentiating Factor; CAK1 Antigen; MPF; Soluble MPF Mesothelin Related Protein; Megakaryocyte Potentiating Factor; SMRP
Function
Membrane-anchored forms may play a role in cellular adhesion.

Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro.
Biological Process
Cell adhesion Source: UniProtKB
Cell-matrix adhesion Source: GO_Central
Pancreas development Source: Ensembl
Cellular Location
Plasma membrane
Cell membrane
Golgi apparatus
Megakaryocyte-potentiating factor:
Secreted
Isoform 3:
Secreted
Involvement in disease
Antibodies against MSLN are detected in patients with mesothelioma and ovarian cancer.
PTM
Both MPF and the cleaved form of mesothelin are N-glycosylated.
Proteolytically cleaved by a furin-like convertase to generate megakaryocyte-potentiating factor (MPF), and the cleaved form of mesothelin.

Hagerty, B. L., & Takabe, K. (2023). Biology of Mesothelin and Clinical Implications: A Review of Existing Literature. World Journal of Oncology, 14(5), 340.

Wang, Q., & Gong, R. (2022). Immunotherapy targeting mesothelin in acute myeloid leukemia. Journal of Leukocyte Biology, 112(4), 813-821.

Schoutrop, E., El-Serafi, I., Poiret, T., Zhao, Y., Gultekin, O., He, R., ... & Mattsson, J. (2021). Mesothelin-specific CAR T cells target ovarian cancer. Cancer Research, 81(11), 3022-3035.

Klampatsa, A., Dimou, V., & Albelda, S. M. (2021). Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert opinion on biological therapy, 21(4), 473-486.

Weidemann, S., Gagelmann, P., Gorbokon, N., Lennartz, M., Menz, A., Luebke, A. M., ... & Simon, R. (2021). Mesothelin expression in human tumors: a tissue microarray study on 12,679 tumors. Biomedicines, 9(4), 397.

Kaeding, A. J., Barwe, S. P., Gopalakrishnapillai, A., Ries, R. E., Alonzo, T. A., Gerbing, R. B., ... & Meshinchi, S. (2021). Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. Blood Advances, 5(9), 2350-2361.

Montemagno, C., Cassim, S., Pouyssegur, J., Broisat, A., & Pagès, G. (2020). From malignant progression to therapeutic targeting: current insights of mesothelin in pancreatic ductal adenocarcinoma. International Journal of Molecular Sciences, 21(11), 4067.

Shen, J., Sun, X., & Zhou, J. (2020). Insights into the role of mesothelin as a diagnostic and therapeutic target in ovarian carcinoma. Frontiers in Oncology, 10, 1263.

Hagemann, U. B., Ellingsen, C., Schuhmacher, J., Kristian, A., Mobergslien, A., Cruciani, V., ... & Cuthbertson, A. S. (2019). Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers. Clinical Cancer Research, 25(15), 4723-4734.

Lv, J., & Li, P. (2019). Mesothelin as a biomarker for targeted therapy. Biomarker Research, 7(1), 1-18.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-MSLN Recombinant Antibody (CBFYM-2650)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare